Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
In Science this week: ancient Neanderthal and human genomes, and more.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
The method allows analysis of copy number at the individual cell level with greater coverage uniformity and more reliable detection than other approaches.
Sales of Helios instruments and genomics analytical consumables were lower than expected, pulling down revenues.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.